Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients., Debie, Yana, Vandamme Timon, and Le Blon Debbie , Clin Cancer Res, 2022 Nov 07, (2022)